BSS, Dhaka :
Bull returned to Dhaka Stock Exchange (DSE) on Tuesday on record rise in transactions, taking the benchmark DSEX index to a 7-month high.
The refreshed momentum stopped the fall of the market, which suffered over 3.0 percent corrections on the previous day profit-booking trading.
The benchmark price index moved like an electrocardiography in the past three trading sessions as it surged on Sunday to a record high and fell on the following day before reaching to the peak in the past seven months after February 13 this year.
The broader DSEX index closed at 4759.39 with a significant 49.48 points recovery driven by bulky transaction of shares across the board.
The investors on the day seemingly ran for the shares of sundry sectors those prices fell to a lucrative positions due to correction on the previous day.
“The actively traded stocks back on track to support the benchmark index towards a new high,” says Lanka Bangla Securities in its market update.
The blue-chip DS30 index also consolidated to rewrite its new height at 1858.40 with phenomenal 39.42 points rise when 80 scrips of this category advanced among the day’s total 114 gainers.
The Shariah compliant DSES index advanced by 15.81 points to 1126.53 as the issues of this category made moderate gains. The mutual fund performed mixed on the day as 12 of the funds gained against 14 losing and another 14 static issues.
The newly listed issues lost the momentum when only a single issue gained and 9 suffered loss among 26 issues traded from this category.
Despite the mixed trend in share prices and the market ended in the negative breadth, the daily trade volume surged to 7-month high of 17 crore shares after February 4 when the daily volume was over 21 crore shares.
The rise in the daily turnover was 25 percent over the previous day, which was driven by the long position on fundamentally sound stocks. Market analysts believed that the activities increased as investors regained their confidence.
“As the prime index stayed above 4700 points level for the third consecutive session with robust turnover, investors were gaining confidence on fresh funds injection,” commented IDLC Finance in its daily market update.
Beximco Pharma was the top turnover leader in value with BSRS Steel, MJL Bangladesh, Beximco Limited and Lafarge Surma among the leading five mostly traded issues. ACI Formulation was the top gainer of the day when the other major advancing issues were Anlima Yarn, Delta Life, RD Food and Beximco Pharma.
BD Building was the worst loser of the day with Eastern Housing, Mozaffar Hossain Spinning Mills, ISN Limited and ICB Sonali 1st MF among the top five losing scrips. Among the major sectors, cement and engineering got investors’ maximum attention while textile lost marginally.
Meanwhile, Bangladesh Securities and Exchange Commission (BSEC) rejected the application of the First Security Islami Bank Limited regarding approval of rights issue as the company failed to comply with the requirement of rule and regulation.
The board of directors of the Central Pharmaceutical recommended 5 percent cash dividend and 15 percent stock dividend for the year ended on June 30, 2014.
Bull returned to Dhaka Stock Exchange (DSE) on Tuesday on record rise in transactions, taking the benchmark DSEX index to a 7-month high.
The refreshed momentum stopped the fall of the market, which suffered over 3.0 percent corrections on the previous day profit-booking trading.
The benchmark price index moved like an electrocardiography in the past three trading sessions as it surged on Sunday to a record high and fell on the following day before reaching to the peak in the past seven months after February 13 this year.
The broader DSEX index closed at 4759.39 with a significant 49.48 points recovery driven by bulky transaction of shares across the board.
The investors on the day seemingly ran for the shares of sundry sectors those prices fell to a lucrative positions due to correction on the previous day.
“The actively traded stocks back on track to support the benchmark index towards a new high,” says Lanka Bangla Securities in its market update.
The blue-chip DS30 index also consolidated to rewrite its new height at 1858.40 with phenomenal 39.42 points rise when 80 scrips of this category advanced among the day’s total 114 gainers.
The Shariah compliant DSES index advanced by 15.81 points to 1126.53 as the issues of this category made moderate gains. The mutual fund performed mixed on the day as 12 of the funds gained against 14 losing and another 14 static issues.
The newly listed issues lost the momentum when only a single issue gained and 9 suffered loss among 26 issues traded from this category.
Despite the mixed trend in share prices and the market ended in the negative breadth, the daily trade volume surged to 7-month high of 17 crore shares after February 4 when the daily volume was over 21 crore shares.
The rise in the daily turnover was 25 percent over the previous day, which was driven by the long position on fundamentally sound stocks. Market analysts believed that the activities increased as investors regained their confidence.
“As the prime index stayed above 4700 points level for the third consecutive session with robust turnover, investors were gaining confidence on fresh funds injection,” commented IDLC Finance in its daily market update.
Beximco Pharma was the top turnover leader in value with BSRS Steel, MJL Bangladesh, Beximco Limited and Lafarge Surma among the leading five mostly traded issues. ACI Formulation was the top gainer of the day when the other major advancing issues were Anlima Yarn, Delta Life, RD Food and Beximco Pharma.
BD Building was the worst loser of the day with Eastern Housing, Mozaffar Hossain Spinning Mills, ISN Limited and ICB Sonali 1st MF among the top five losing scrips. Among the major sectors, cement and engineering got investors’ maximum attention while textile lost marginally.
Meanwhile, Bangladesh Securities and Exchange Commission (BSEC) rejected the application of the First Security Islami Bank Limited regarding approval of rights issue as the company failed to comply with the requirement of rule and regulation.
The board of directors of the Central Pharmaceutical recommended 5 percent cash dividend and 15 percent stock dividend for the year ended on June 30, 2014.
